Effectiveness of an 8-Week Low-FODMAP Diet in Improving Gastrointestinal Symptoms and Health-Related Quality of Life in Adults with Irritable Bowel Syndrome: A Randomized Controlled Trial
Journal of Advances in Science and Technology · 01.06.2026 · 23 (2) · 141-156
DOI: 10.29070/kq12ej70 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Advances in Science and Technology, online erschienen am 01.06.2026. Verfasst von Sarika Giria und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Irritable bowel syndrome (IBS) is one of the most prevalent disorders of gut–brain interaction and is characterized by recurrent abdominal pain associated with altered bowel habits. Because dietary triggers frequently exacerbate IBS symptoms, dietary modification has become an important component of clinical management. Restriction of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) has emerged as an evidence-based therapeutic strategy; however, further randomized controlled studies are needed to evaluate its effectiveness in different populations.
Objective
To evaluate the effectiveness of an 8-week Low-FODMAP dietary intervention on gastrointestinal symptoms and patient-reported outcomes in adults with IBS.
Methods
A single-blind randomized controlled trial was conducted between March and May 2025. Sixty adults diagnosed with IBS according to the Rome IV criteria were randomly allocated to either a Low-FODMAP diet group (n = 30) or a standard dietary advice group (n = 30). Participants in the intervention group received individualized dietary counselling and followed a structured Low-FODMAP diet for eight weeks, whereas the control group continued their habitual diet with general healthy eating advice. Gastrointestinal symptoms were assessed at baseline and after the intervention using a validated symptom questionnaire. Within-group comparisons were performed using paired t-tests, and statistical significance was established at p < 0.05.
Results
Participants assigned to the Low-FODMAP diet demonstrated significant improvement in 14 of the 17 assessed symptom domains following the intervention. Marked improvements were observed in abdominal discomfort, bloating, bowel habits, excessive gas, stool consistency, and overall symptom burden. Paired t-test values ranged from 2.504 to 8.226 (p < 0.05). In contrast, participants receiving standard dietary advice showed minimal changes, with statistically significant improvement observed in only two symptom domains. Crosstab analyses further demonstrated significant reductions in bowel urgency, harder stools, and excessive gas in the intervention group, whereas no significant improvements were observed in the control group.
Conclusions
An eight-week Low-FODMAP dietary intervention significantly improved gastrointestinal symptoms and patient-reported outcomes among adults with IBS. These findings support the integration of structured Low-FODMAP dietary counselling into routine clinical management of IBS. Larger multicentre studies with longer follow-up are warranted to determine long-term effectiveness and sustainability.
Zitieren
APA
Giria, S., & Shekhawat, P. S. (2026). Effectiveness of an 8-Week Low-FODMAP Diet in Improving Gastrointestinal Symptoms and Health-Related Quality of Life in Adults with Irritable Bowel Syndrome: A Randomized Controlled Trial. Journal of Advances in Science and Technology, 23(2), 141-156. https://doi.org/10.29070/kq12ej70
Vancouver
Giria S, Shekhawat PS. Effectiveness of an 8-Week Low-FODMAP Diet in Improving Gastrointestinal Symptoms and Health-Related Quality of Life in Adults with Irritable Bowel Syndrome: A Randomized Controlled Trial. Journal of Advances in Science and Technology. 2026;23(2):141-156. doi:10.29070/kq12ej70
BibTeX
@article{Giria2026,
author = {Giria, Sarika and Shekhawat, Pradyumna Singh},
title = {Effectiveness of an 8-Week Low-FODMAP Diet in Improving Gastrointestinal Symptoms and Health-Related Quality of Life in Adults with Irritable Bowel Syndrome: A Randomized Controlled Trial},
journal = {Journal of Advances in Science and Technology},
year = {2026},
volume = {23},
number = {2},
pages = {141--156},
doi = {10.29070/kq12ej70}
}
EUVIMED